Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STArT: Arginine Therapy for Sickle Cell Disease
NCT04839354Phase 3Completed
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of arginine in sickle cell disease (SCD). Started Jun 2021; status: completed.
02
Drugs
arginine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04839354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839354.